Trial · NCT02400463

A Pilot Study of Ruxolitinib in Secondary Hemophagocytic Syndrome

NCT02400463, Phase 2, Completed, University of Michigan Rogel Cancer Center; results first posted 2020-11-18

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. A Pilot Study of Ruxolitinib in Secondary Hemophagocytic Syndrome. Trials, record NCT02400463. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02400463

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: A Pilot Study of Ruxolitinib in Secondary Hemophagocytic Syndrome
NCT number: NCT02400463
Status: Completed
Phases: Phase 2
Enrollment: 6 participants, actual
Lead sponsor: University of Michigan Rogel Cancer Center
Conditions: Hemophagocytic Syndrome (HPS)
Interventions: Ruxolitinib
First posted: 2015-03-27
Last updated: 2021-01-25
Results first posted: 2020-11-18

Source ClinicalTrials.gov

Registered outcomes5

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Overall Survival at 2 Months	2 Months	Number of Patients Alive at 2 Months after the first administration of ruxolitinib.
Secondary	Percentage of Patients With a Response to Treatment With Ruxolitinib	2 Months	Complete response is defined as complete normalization of all quantifiable symptoms and laboratory abnormalities. A partial response is defined as at least a 25% improvement in two or more quantifiable symptoms/laboratory markers.
Secondary	Duration of Response	Up to 3 years (Due to funding and other constraints, participant follow-up was discontinued in 2020. Thus, not all participants were followed for a full three years.)	Duration will be calculated from the date of the determination of partial response or better until the date of progression, death, or additional non-protocol therapy.
Secondary	Progression Free Survival Time	Up to 3 years (Due to funding and other constraints, participant follow-up was discontinued in 2020. Thus, not all participants were followed for a full three years.)	Progressive Disease is defined as at least a 50% worsening in two or more quantifiable laboratory markers. Calculated from the first administration of ruxolitinib until the date of progression or death.
Secondary	Regimen Related Toxicities	Up to 30 days after last treatment administration	Incidence and grade of adverse events (AEs) unlikely, possibly or probably related to treatment (tx) with ruxolitinib. Graded per Common Terminology Criteria for Adverse Events (CTCAE) v.4. Grade refers to the severity of the AE, from mild (grade 1) to life-threatening (grade 4).

Source ClinicalTrials.gov

Outcomes5

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Units	Measured as
PRIMARY	Overall Survival at 2 Months	2 Months	Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Percentage of Patients With a Response to Treatment With Ruxolitinib	2 Months	percentage of participants	NUMBER
SECONDARY	Duration of Response	Up to 3 years (Due to funding and other constraints, participant follow-up was discontinued in 2020. Thus, not all participants were followed for a full three years.)	months	MEDIAN
SECONDARY	Progression Free Survival Time	Up to 3 years (Due to funding and other constraints, participant follow-up was discontinued in 2020. Thus, not all participants were followed for a full three years.)	months	MEDIAN
SECONDARY	Regimen Related Toxicities	Up to 30 days after last treatment administration	Adverse Events	NUMBER

Source ClinicalTrials.gov

Results by group8

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Spread	Units
Overall Survival at 2 Months	Ruxolitinib		6		Participants
Percentage of Patients With a Response to Treatment With Ruxolitinib	Ruxolitinib		100		percentage of participants
Duration of Response	Ruxolitinib		17.25	Full Range 3.5 to 35.5	months
Progression Free Survival Time	Ruxolitinib		17.25	Full Range 3.5 to 35.5	months
Regimen Related Toxicities	Ruxolitinib	Grade 1	5		Adverse Events
Regimen Related Toxicities	Ruxolitinib	Grade 2	3		Adverse Events
Regimen Related Toxicities	Ruxolitinib	Grade 3	1		Adverse Events
Regimen Related Toxicities	Ruxolitinib	Grade 4	1		Adverse Events

Source ClinicalTrials.gov

Participant flow3

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Ruxolitinib	6
Overall Study	COMPLETED	Ruxolitinib	6
Overall Study	NOT COMPLETED	Ruxolitinib	0

Source ClinicalTrials.gov

Adverse events46

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Blood and lymphatic system disorders - Other, specify	Blood and lymphatic system disorders	Ruxolitinib	2	6	2
other	Ear and labyrinth disorders - Other, specify	Ear and labyrinth disorders	Ruxolitinib	1	6	1
other	Cushingoid	Endocrine disorders	Ruxolitinib	1	6	1
other	Abdominal pain	Gastrointestinal disorders	Ruxolitinib	2	6	2
other	Constipation	Gastrointestinal disorders	Ruxolitinib	2	6	2
other	Dysphagia	Gastrointestinal disorders	Ruxolitinib	1	6	1
other	Gastrointestinal disorders - Other, specify	Gastrointestinal disorders	Ruxolitinib	1	6	1
other	Nausea	Gastrointestinal disorders	Ruxolitinib	2	6	3
other	Fatigue	General disorders	Ruxolitinib	3	6	4
other	Fever	General disorders	Ruxolitinib	1	6	2

1 to 10 of 46Source ClinicalTrials.gov

See all 46 adverse events

Adverse event totals3

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Ruxolitinib	0	6
Total, other adverse events	Ruxolitinib	6	6
Total, serious adverse events	Ruxolitinib	2	6

Source ClinicalTrials.gov

Papers1

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as
31537486	DERIVED

Source PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT02400463

GET https://conductscience.org/api/trials/v1/NCT02400463/events?page=2

API reference For AI assistants